Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct OfferingPRNewsWire • 07/17/23
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development OfficerPRNewsWire • 07/12/23
BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of NeurodegenerationPRNewsWire • 07/07/23
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee ChairPRNewsWire • 06/20/23
BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual ConferencePRNewsWire • 06/16/23
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023PRNewsWire • 06/06/23
BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development SummitPRNewsWire • 05/19/23
BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 05/15/23
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate UpdatePRNewsWire • 05/09/23
BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical OfficerPRNewsWire • 04/24/23
BrainStorm: Upcoming AdCom Meeting For NurOwn For ALS Could Be Start Of Major TurnaroundSeeking Alpha • 03/30/23
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate UpdatePRNewsWire • 03/30/23
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALSPRNewsWire • 03/27/23
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate UpdatePRNewsWire • 03/21/23
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS StudyPRNewsWire • 01/10/23
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive OfficerPRNewsWire • 01/04/23
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn®PRNewsWire • 12/27/22
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug AdministrationPRNewsWire • 12/12/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLIPRNewsWire • 12/06/22
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate UpdatePRNewsWire • 11/14/22